Industry Trend Analysis - Foreign Funding To Drive R&D In NTDs - JUNE 2017


BMI View : Increased funding will drive research and development into some of the more common neglected tropical diseases ( NTDs ) . However, funding for NTDs will rely on foreign investors , as the low-income countries affected are concentrating funding on preventive measures and treatments for infectious diseases , which cause a greater burden on the countr ies . Smaller NTDs will struggle to meet the WHO ' s elimination target of 2020 without increased private funding.

The World Health Organization (WHO) reports remarkable achievements in tackling neglected tropical diseases (NTDs) since 2007; an estimated 1bn people received treatment in 2015 alone. Since 2007, when a group of global partners met to agree to tackle NTDs together, a variety of local and international partners have worked alongside ministries of health in endemic countries to deliver quality-assured medicines, and provide people with care and long-term management. In 2012, partners endorsed a WHO NTD roadmap, committing additional support and resources to eliminating 10 of the most common NTDs. In April 2017, the WHO released a report entitled 'Integrating neglected tropical diseases in global health and development', which demonstrates how strong political support, generous donations of medicines, and improvements in living conditions have led to sustained expansion of disease control programmes in countries where these diseases are most prevalent.

Global Burden Of NTDs

NTDs Still Highly Prevalent
Number Of People Requiring Preventive Chemotherapy (mn)
LF = lymphatic filariasis, ONCHO = onchocerciasis, SCH = schistosomiasis, STH = soil-transmitted helminthiases, TRA = trachoma. Source: WHO, BMI

This article is part of our Middle East & Africa coverage. To access this article subscribe now or sign up for free trial